AstraZeneca 1Q Earnings, Revenue Rose; Backs 2021 Outlook
30 April 2021 - 8:52AM
Dow Jones News
By Cecilia Butini
AstraZeneca PLC said Friday that sales and earnings rose in the
first quarter, and backed its 2021 outlook.
The pharmaceutical giant said net profit rose to $1.56 billion
from $780 million the year prior.
Operating profit came in at $1.90 billion compared with $1.22
billion the previous year, while after-tax profit stood at $1.56
billion, up from $750 million, it said.
Sales for the period climbed to $7.32 billion from $6.35
billion, the company said.
Earnings per share were $1.18 in the quarter, versus $0.59 in
the same quarter in 2020. The company said the development of its
coronavirus vaccine had a negative $0.03 impact on EPS in the
quarter.
AstraZeneca backed a previously given outlook for the full year,
which was for total revenue increasing by a low-teens percentage,
and core earnings per share rising to $5.00 from $4.00, all at
constant exchange rates. It said that the guidance doesn't
incorporate revenue or profit impact from sales of the Covid-19
vaccine, and that it also excludes the proposed acquisition of
Alexion Pharmaceuticals Inc.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 30, 2021 02:37 ET (06:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
